Efficacy and safety of pemetrexed versus erlotinib in the second-line treatment of patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene

Trial Profile

Efficacy and safety of pemetrexed versus erlotinib in the second-line treatment of patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2016

At a glance

  • Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2016 New trial record
    • 01 Jan 2016 Results published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top